Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | CSGALNACT1 | Q8TDX6 | 7/20 | 0.33 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.32 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23041511 | 1.00 | MME (0.38) | MMEDGAT1CSGALNACT1GPR132USP30 | |
| SCHEMBL28722565 | 0.93 | MME (0.36) | MMEDGAT1CSGALNACT1GPR132USP30 | |
| SCHEMBL28722717 | 0.93 | MME (0.36) | MMEDGAT1CSGALNACT1GPR132USP30 | |
| SCHEMBL23041569 | 0.93 | MME (0.36) | MMEDGAT1CSGALNACT1GPR132USP30 | |
| SCHEMBL23041646 | 0.93 | MME (0.36) | MMEDGAT1CSGALNACT1GPR132USP30 | |
| SCHEMBL23041566 | 0.93 | MME (0.36) | MMEDGAT1CSGALNACT1GPR132USP30 | |
| SCHEMBL23041649 | 0.93 | MME (0.36) | MMEDGAT1CSGALNACT1GPR132USP30 | |
| SCHEMBL23051954 | 0.92 | TACR3 (0.34) | MMEUSP30ACACBACACA | |
| SCHEMBL23051952 | 0.92 | TACR3 (0.34) | MMEUSP30ACACBACACA | |
| SCHEMBL29452820 | 0.92 | TACR3 (0.34) | MMEUSP30ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | claimed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | claimed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | disclosed |